| Style | Citing Format |
|---|---|
| MLA | Safarnezhad Tameshkel F, et al.. "An Integrative Transcriptomic Analysis for Prognosis and Tumor Microenvironment in Hbv/Hcv-Associated Hepatocellular Carcinoma." Molecular Therapy Oncology, vol. 34, no. 2, 2026, pp. -. |
| APA | Safarnezhad Tameshkel F, Sadat Kalaki N, Karimi E, Razizadeh MH, Haidar AEH, Amiri A, Zaki M, Nikkhah M, Karbalaie Niya MH (2026). An Integrative Transcriptomic Analysis for Prognosis and Tumor Microenvironment in Hbv/Hcv-Associated Hepatocellular Carcinoma. Molecular Therapy Oncology, 34(2), -. |
| Chicago | Safarnezhad Tameshkel F, Sadat Kalaki N, Karimi E, Razizadeh MH, Haidar AEH, Amiri A, Zaki M, Nikkhah M, Karbalaie Niya MH. "An Integrative Transcriptomic Analysis for Prognosis and Tumor Microenvironment in Hbv/Hcv-Associated Hepatocellular Carcinoma." Molecular Therapy Oncology 34, no. 2 (2026): -. |
| Harvard | Safarnezhad Tameshkel F et al. (2026) 'An Integrative Transcriptomic Analysis for Prognosis and Tumor Microenvironment in Hbv/Hcv-Associated Hepatocellular Carcinoma', Molecular Therapy Oncology, 34(2), pp. -. |
| Vancouver | Safarnezhad Tameshkel F, Sadat Kalaki N, Karimi E, Razizadeh MH, Haidar AEH, Amiri A, et al.. An Integrative Transcriptomic Analysis for Prognosis and Tumor Microenvironment in Hbv/Hcv-Associated Hepatocellular Carcinoma. Molecular Therapy Oncology. 2026;34(2):-. |
| BibTex | @article{ author = {Safarnezhad Tameshkel F and Sadat Kalaki N and Karimi E and Razizadeh MH and Haidar AEH and Amiri A and Zaki M and Nikkhah M and Karbalaie Niya MH}, title = {An Integrative Transcriptomic Analysis for Prognosis and Tumor Microenvironment in Hbv/Hcv-Associated Hepatocellular Carcinoma}, journal = {Molecular Therapy Oncology}, volume = {34}, number = {2}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Safarnezhad Tameshkel F AU - Sadat Kalaki N AU - Karimi E AU - Razizadeh MH AU - Haidar AEH AU - Amiri A AU - Zaki M AU - Nikkhah M AU - Karbalaie Niya MH TI - An Integrative Transcriptomic Analysis for Prognosis and Tumor Microenvironment in Hbv/Hcv-Associated Hepatocellular Carcinoma JO - Molecular Therapy Oncology VL - 34 IS - 2 SP - EP - PY - 2026 ER - |